Atlas Trials

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

Clinical trial NCT05477524 · COMPLETED

Trial details

NCT number
NCT05477524
Sponsor
Pfizer
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Lyme Disease
Start date
2022-08-04
Primary completion
2026-01-07
Enrollment
12546

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.